eCite Digital Repository

Inflammasomes as therapeutic targets for Alzheimer's disease

Citation

White, CS and Lawrence, CB and Brough, D and Rivers-Auty, J, Inflammasomes as therapeutic targets for Alzheimer's disease, Brain Pathology, 27, (2) pp. 223-234. ISSN 1015-6305 (2017) [Refereed Article]


Preview
PDF (Post-print)
940Kb
  

Copyright Statement

Copyright 2016 International Society of Neuropathology. This is the peer reviewed version of the following article: White, C. S., Lawrence, C. B., Brough, D., Rivers-Auty, J., 2017. Inflammasomes as therapeutic targets for Alzheimer's disease, Brain Pathology, 27(2), 223-234 which has been published in final form at https://doi.org/10.1111/bpa.12478. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

DOI: doi:10.1111/bpa.12478

Abstract

Alzheimer's disease is the most common form of progressive dementia, typified initially by short term memory deficits which develop into a dramatic global cognitive decline. The classical hall marks of Alzheimer's disease include the accumulation of amyloid oligomers and fibrils, and the intracellular formation of neurofibrillary tangles of hyperphosphorylated tau. It is now clear that inflammation also plays a central role in the pathogenesis of the disease through a number of neurotoxic mechanisms. Microglia are the key immune regulators of the CNS which detect amyloidopathy through cell surface and cytosolic pattern recognition receptors (PRRs) and respond by initiating inflammation through the secretion of cytokines such as interleukin-1β (IL-1β). Inflammasomes, which regulate IL-1β release, are formed following activation of cytosolic PRRs, and using genetic and pharmacological approaches, NLRP3 and NLRP1 inflammasomes have been found to be integral in pathogenic neuroinflammation in animal models of Alzheimer's disease. Therefore, the inflammasomes are very promising novel pharmacological targets which merit further research in the continued endeavor for efficacious therapeutics for Alzheimer's disease.

Item Details

Item Type:Refereed Article
Keywords:Alzheimer's disease, NSAID, inflammation, NLRP3
Research Division:Medical and Health Sciences
Research Group:Immunology
Research Field:Innate Immunity
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Neurodegenerative Disorders Related to Ageing
UTAS Author:Rivers-Auty, J (Dr Jack Auty)
ID Code:135834
Year Published:2017
Web of Science® Times Cited:30
Deposited By:Medicine
Deposited On:2019-11-15
Last Modified:2019-12-06
Downloads:2 View Download Statistics

Repository Staff Only: item control page